Found 162 articles for: "infliximab"
Pyoderma Gangrenosum Following Breast Reconstructive Surgery: A Case Report of Treatment With Immunosuppression and Adjunctive Xenogeneic Matrix Scaffolds
May 2011 | Volume 10 | Issue 5 | Original Article | 545 | Copyright © May 2011
Infliximab Treatment for Psoriasis in 120 Patients on Therapy for a Minimum of One Year: A Review
May 2011 | Volume 10 | Issue 5 | Original Article | 539 | Copyright © May 2011
Infliximab is a chimeric monoclonal antibody, which acts by binding to both the soluble and membrane-bound tumor necrosis factor-a. In clinical prac...
Read MoreAn Open-Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab
April 2011 | Volume 10 | Issue 4 | Original Article | 396 | Copyright © April 2011
Background: The past several years have seen the approval of five different biologic agents for the treatment of moderate to severe plaque p...
Read MoreTreatment of Hidradenitis Suppurativa by Photodynamic Therapy With Aminolevulinic Acid: Preliminary Results
April 2011 | Volume 10 | Issue 4 | Original Article | 381 | Copyright © April 2011
Background: The current standard of care for hidradenitis suppurativa (HS) includes antibiotics (oral/topical), retinoids (oral/topical) and...
Read MoreAdalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis
April 2011 | Volume 10 | Issue 4 | Original Article | 366 | Copyright © April 2011
Background: Combining systemic agents with phototherapy is becoming a standard of care for patients with moderate to severe psoriasis. The c...
Read MoreClinical Trial Safety and Mortality Analyses in Patients Receiving EtanerceptAcross Approved Indications
March 2011 | Volume 10 | Issue 3 | Original Article | 289 | Copyright © March 2011
Objectives: Assessment of associations between etanercept treatment and rare adverse events has been limited by the size of clinical trial populations. The authors examined the collective safe...
Read MoreFrequency of Thrombocytopenia in Psoriasis Patients Treated With Tumor Necrosis Factor-α Inhibitors
March 2011 | Volume 10 | Issue 3 | Original Article | 280 | Copyright © March 2011
Tumor necrosis factor-α (TNF-α) inhibitors are biologic agents that are currently in wide use for the treatment of psoriasis as well as other inflammatory diseases. Following reports of thro...
Read MoreRapid Improvement of Pyoderma Gangrenosum After Treatment With Infliximab
June 2010 | Volume 9 | Issue 6 | Case Reports | 702 | Copyright © June 2010
Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing re...
Read MoreAtypical Presentation of Histoplasmosis in a Patient With Psoriasisand Psoriatic Arthritis on Infliximab Therapy
January 2010 | Volume 9 | Issue 1 | Case Reports | 57 | Copyright © January 2010
Infliximab is a chimeric monoclonal antibody to TNF-α which acts on both the soluble and transmembrane forms of TNF-α. It has been used successfully for the treatment of psoriasis and psori...
Read MoreInduction of Lesional and Circulating Leukocyte Apoptosis by Infliximab in a Patient with Moderate to Severe Psoriasis
October 2006 | Volume 5 | Issue 9 | Case Reports | 890 | Copyright © October 2006
Infliximab demonstrates high efficacy in treating psoriasis in a high proportion of patients. In this report we demonstrate induction of plaque (T cells, dendritic cells) and peripheral blood (T cell...
Read MoreBiologic Therapy for Psoriasis: An Update on the Tumor Necrosis Factor Inhibitors Infliximab, Etanercept, and Adalimumab, and the T-Cell-Targeted Therapies Efalizumab and Alefacept
September 2005 | Volume 4 | Issue 5 | Original Article | 544 | Copyright © September 2005
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the developm...
Read MoreSustained Efficacy and Safety of Infliximab in Psoriasis: A Retrospective Study of 73 Patients
March 2006 | Volume 5 | Issue 3 | Original Article | 251 | Copyright © March 2006
Background: Infliximab inhibits T-cell activation by binding tumor necrosis factor-? (TNF-?). This medication is widely used in the US for treatment of psoriasis as an off-label indication. The durab...
Read MoreLife-Threatening Pustular and Erythrodermic Psoriasis Responding to Infliximab
June 2006 | Volume 5 | Issue 6 | Case Reports | 546 | Copyright © June 2006
Pustular and erythrodermic psoriasis can be a debilitating and recalcitrant disease which may result in secondary complications such as sepsis, electrolyte imbalance, renal failure, and heart failure...
Read MoreInfliximab Associated New-Onset Psoriasis
February 2006 | Volume 5 | Issue 2 | Case Reports | 178 | Copyright © February 2006
Infliximab infusion is not yet FDA-approved for psoriasis but has been reported to be very effective for plaque psoriasis. We report 2 patients without a history of psoriasis who after administration...
Read MorePustular Psoriasis Induced by Infliximab
July 2004 | Volume 3 | Issue 4 | Case Reports | 439 | Copyright © July 2004
Pustular psoriasis is an uncommon variant of psoriasis characterized by widespread pustules on an erythematous background. Recent reports document the efficacy of immunobiologic agents such as inflix...
Read MoreCounter-Regulatory Balance: Atopic Dermatitis in Patients Undergoing Infliximab Infuson Therapy
May 2004 | Volume 3 | Issue 3 | Case Reports | 315 | Copyright © May 2004
Atopic dermatitis has been characterized as an autoimmune or auto-allergic phenomenon in which environmental allergens resembling human proteins activate auto-reactive T-cells to release pro-inflamma...
Read MoreSerum Sickness due to Infliximab in a Patient with Psoriasis
May 2004 | Volume 3 | Issue 3 | Case Reports | 305 | Copyright © May 2004
Infliximab is a chimeric, murine-human, monoclonal antibody against tumor necrosis alpha which has shown great efficacy in the treatment of psoriasis. Serum sickness, which is an immune complex media...
Read MoreOff-label Uses and Side Effects of Infliximab
May 2004 | Volume 3 | Issue 3 | Original Article | 273 | Copyright © May 2004
Infliximab was first approved by the FDA in 1998 as a treatment of moderately-to-severely active Crohn’s disease in patients who have an inadequate response to conventional therapies, and fistulizi...
Read MoreThe Use of Tinfliximab in Cutaneous Sarcoidosis
August 2003 | Volume 2 | Issue 4 | Case Reports | 413 | Copyright © August 2003
Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-?, has recently shown efficacy in the treatment of refractory sarcoidosis1,2. The manifestations of sarcoi...
Read MoreBiologic Therapy for Psorasis- The First Wave: Infliximab, Etanercept, Efalizumab, and Alefacept
December 2002 | Volume 1 | Issue 3 | Original Article | 303 | Copyright © December 2002
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the infla...
Read More